Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Glenn Preminger

Urology Durham, NC Medical Doctor

NPI 1255415147 CMS profile 283912

2100 Erwin Road, Durham, NC 27710

Open in the dashboard

General payments

$736,400

206 records reported · program years 2019–2025

Research payments

$1,900

Paid to them · 2 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Glenn Preminger of Durham, NC is reported in the CMS Open Payments database as having received $736,400 across 206 general payments and $1,900 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,014 3
2024 General $1,775 2
2023 General $10,954 13
2022 General $35,880 39
2021 General $31,943 19
2021 Research $950 1
2020 General $88,508 38
2020 Research $950 1
2019 General $566,327 92

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Glenn Preminger
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Glenn Preminger were reported at $1,014. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Glenn Preminger Urology median Middle half National median
2019 $566,327 $480 $147–$1,201 $163
2020 $88,508 $246 $87–$645 $114
2021 $31,943 $358 $111–$1,000 $132
2022 $35,880 $476 $143–$1,263 $149
2023 $10,954 $560 $168–$1,461 $160
2024 $1,775 $563 $170–$1,464 $164
2025 $1,014 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Ethicon Inc. $539,450 22 payments
  2. Boston Scientific Corporation $148,921 98 payments
  3. Retrophin, Inc. $33,153 56 payments
  4. Merck Sharp & Dohme Corporation $7,925 11 payments
  5. Calyxo, Inc. $4,670 13 payments
  6. Kowa Pharmaceuticals America, Inc. $960 1 payment
  7. Olympus Winter & Ibe GmbH $875 1 payment
  8. Dr.Reddy's Laboratories,Inc. $222 1 payment
  9. Cook Medical LLC $97 1 payment
  10. Olympus America Inc. $66 1 payment
  11. Other $61 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $599,462 37 payments
  2. Consulting Fee $97,317 49 payments
  3. Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program $25,700 12 payments
  4. Travel and Lodging $9,898 48 payments
  5. Food and Beverage $4,023 60 payments
Products named General payments · program years 2019–2025
  1. General - Kidney Stone Disease Kidney Stone Disease $32,663 11 payments
  2. (815) Thiola $30,653 55 payments
  3. GENERAL KIDNEY STONE DISEASE Pain Management $24,427 15 payments
  4. LITHOVUE $20,910 10 payments
  5. Monarch Platform Endo-Mechanical $19,598 10 payments
  6. General Therapies $17,004 9 payments
  7. GENERAL KIDNEY STONE DISEASE Kidney Stone Disease $15,339 14 payments
  8. General - Kidney Stone Disease General - Kidney Stone Disease_URO $13,776 14 payments
  9. Monarch Platform Endo-Mechanical $11,900 3 payments
  10. ADVANCE $9,000 2 payments
  11. Other $13,762 36 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. US Endoscopy $1,900 2 payments

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

448

Median for Urology: 1,053

Drug cost

$41,643

Median for Urology: $101,464

Branded share of claims

62.3%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Potassium Citrate Er Potassium Citrate Brand 267 $38,777
Chlorthalidone Generic 101 $1,465
Tamsulosin Hcl Generic 48 $672
Oxybutynin Chloride Er Oxybutynin Chloride Brand 12 $486
Allopurinol Generic 20 $243

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 10 billing codes

Paid by Medicare

$13,629

Medicare's payments for the services billed

Medicare patients

131

Average age 72

Services billed

308

56 women, 75 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Chronic kidney disease 45%
Arthritis 43%
Diabetes 33%
Ischemic heart disease 24%
Cancer 23%
Depression 19%
Atrial fibrillation 13%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

208 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record